Morgan Stanley lowered the firm’s price target on RXO Inc. (RXO) to $21 from $23 and keeps an Equal Weight rating on the shares. The firm believes Q2 results for companies in the North America Freight Transporation industry will be much better than anticipated three months ago, but will likely still not be enough for investors, the analyst tells investors. While the firm would be surprised to see fiscal year guides restored, there is the possibility of the return of investor interest if there is strong July commentary.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXO:
- RXO, Inc. Faces Mixed Performance and Regulatory Challenges: Hold Rating with Cautious Outlook
- RXO Inc. price target raised to $12 from $10 at Susquehanna
- RXO Inc. management to meet with Benchmark
- RXO, Inc. Hold Rating: Balancing Stable Demand and Market Uncertainties
- RXO, Inc. Holds 2025 Annual Stockholders Meeting